Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Clinical trial NCT03748186 · COMPLETED

Trial details

NCT number: NCT03748186
Sponsor: Sutro Biopharma, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Ovarian Cancer Ovarian Carcinoma Ovary Cancer Endometrial Cancer Endometrioid Adenocarcinoma Fallopian Tube Cancer Primary Peritoneal Carcinoma

Start date: 2019-02-01
Primary completion: 2024-06-04
Enrollment: 136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.